Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
UCLA Santa Monica Hematology Oncology, Santa Monica, California Winship Cancer Institute at Emory University, Atlanta, Georgia Ochsner Health, Jefferson, Louisiana START Midwest, Grand Rapids, Michigan Washington University School of Medicine, St Louis, Missouri Hackensack University Medical Center, Hackensack, New Jersey Roswell Cancer Institute, Buffalo, New York Memorial Sloan Kettering Cancer Center, New York, New York University Hospitals - UH Cleveland Medical Center, Cleveland, Ohio NEXT Oncology Dallas, Irving, Texas NEXT Oncology Virginia, Fairfax, Virginia France
Site FR33003, Bordeaux, New Aquitaine Site FR33004, Pierre-Bénite Japan
Cancer Institute Hospital of JFCR, Koto-ku, Tokyo Spain
Site ES34005, Barcelona, Catalonia